Basic Information


GTO ID GTC1801
Trial ID NCT03313778
Disease Solid Tumor
TherapymRNA vaccine
Treatment V940|mRNA-4157
PhasePhase1
Recruitment statusRecruiting
TitleA Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Year2017
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-4157-P101|2023-505192-77-00
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: mRNA-4157_up to 9 cycles
Administration route intramuscular injection
Dosage mRNA-4157, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult
Cohort2: mRNA-4157_Pembrolizumab_up to 35 cycles
Administration route intramuscular injection|intravenous infusion
Dosage mRNA-4157, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult
Cohort3: mRNA-4157_SoC Treatment
Administration route intramuscular injection|intravenous infusion
Dosage mRNA-4157, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult
Cohort5: mRNA-4157_Pembrolizumab_up to 18 cycles
Administration route intramuscular injection|intravenous infusion
Dosage mRNA-4157, Day 1 of each 21-day cycle for up to 9 cycles
Age Adult, Older_Adult
Cohort6: mRNA-4157_Pembrolizumab_SoC Treatment_Q3W
Administration route intramuscular injection|intravenous infusion
Dosage mRNA-4157, Day 1 of each 21-day cycle
Age Adult, Older_Adult
Cohort7: mRNA-4157_Pembrolizumab_SoC Treatment_Q2W or Q3W
Administration route intramuscular injection|intravenous infusion
Dosage mRNA-4157, Day 1 of each 21-day cycle
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph